Navigation Links
BridgePoint Medical Announced 510(k) Clearance for an Expanded Indication to Treat Coronary Chronic Total Occlusions
Date:5/16/2011

MINNEAPOLIS, May 16, 2011 /PRNewswire/ -- BridgePoint Medical, Inc., a Minnesota-based medical device company, has announced that they have received clearance of an expanded indication for the CrossBoss™ Catheter and Stingray™ System from the FDA.  The expanded indication includes the intraluminal placement of conventional guidewires beyond stenotic coronary lesions [including chronic total occlusions (CTOs)] prior to PTCA or stent intervention.  CTOs are chronically stenosed lesions that completely block a coronary artery – typically for 3 months or longer - and prevent blood circulation to critical areas of the heart.  

Company Founder & COO Chad Kugler reflected, "This is the culmination of 5 years of development, clinical and regulatory work.  We are grateful for the opportunity to market these products for the specific challenge they were developed for and confident that we have created a great solution for treating CTOs."

This expanded indication is the result of data generated from the 147-patient FAST-CTOs clinical trial in which the safety and effectiveness of the system in coronary chronic total occlusions was demonstrated.

Dr. William Lombardi of St. Joseph's Hospital in Bellingham, WA and a leading enroller in the clinical trial states, "The BridgePoint system is the first set of devices designed specifically for treating coronary Chronic Total Occlusions that has shown real improvements in safety, procedural efficiency, and clinical success rates.  The clinical trial has proven that these arteries can be opened effectively with these products and now with the expanded indication from the FDA there will be a new level of awareness among physicians and patients."

BridgePoint's ability to commercialize its CrossBoss™ Catheter and Stingray™ System will be greatly expanded with this new level of indication.  BridgePoint is the first interventional device company to be granted this specific type of approval for both crossing and re-entry technologies to be used in the treatment of coronary CTOs.

Company CEO and President Denis Harrington says, "We are excited about the expanded indication.  The FAST-CTO Trial demonstrated the safety and effectiveness of the CrossBoss Catheter and Stingray System in treating these most challenging lesions – CTOs.  And we are poised to be the leader in helping physicians treat these patients."

About BridgePoint Medical:

BridgePoint Medical, Inc. is a privately held company established in 2006 to design, develop and commercialize new technologies and techniques to treat challenging coronary and peripheral artery disease.  Investors include New Enterprise Associates, Polaris Venture Partners, Foundation Medical Partners and Michael Berman.


'/>"/>
SOURCE BridgePoint Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BridgePoint Medical Names Industry Veteran as Chief Executive Officer
2. BridgePoint Medical Closes $9.1 Million Series C Financing
3. BridgePoint Medical®, Inc. Completes and Submits to FDA in the U.S. FAST-CTOs With the CrossBoss® and Stingray® CTO Recanalization System
4. BridgePoint Medical(R) Receives European CE Mark for Stingray(R) and CrossBoss(TM) for Opening Completely Blocked Arteries
5. UBM Canon Medical Device Content Team Announces Upcoming Virtual Event Content Topics
6. FDA Formally Accepts Dune Medicals MarginProbe™ System Pre-Market Approval (PMA) Application and Grants Expedited Review Status
7. STMicroelectronics Reveals Best-in-Class Technology Enabling Longer-Lasting Broadcast and Medical-Imaging Equipment
8. Reportlinker Adds Impact of Healthcare Reforms on the Medical Technology Industry
9. Winner Medical to Present at Oppenheimer 5th Annual China Dragon Conference
10. Royce Receives Coveted Medical Products Award
11. Medical Care Technologies Inc. Selects Geographical Location for Flagship Childrens Health Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... BOSTON , March 27, 2017 /PRNewswire/ ... company and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a ... of innovative therapies based upon tetracycline chemistry, announced ... for the treatment of moderate to severe acne ... is a once-daily, oral, narrow spectrum tetracycline-derived antibiotic ...
(Date:3/27/2017)... -- Impax Laboratories, Inc. (NASDAQ: IPXL)today announced that its Board ... as Impax,s President and Chief Executive Officer and a ... Mr. Bisaro will succeed J. Kevin Buchi , ... Officer since December of 2016. With ... Bisaro, 56, is an accomplished global business leader who ...
(Date:3/27/2017)... , March 27, 2017  PhaseRx, Inc. ... for life-threatening inherited liver diseases in children, today ... full year ended December 31, 2016 and provided ... "PhaseRx continued to make progress during the ... positive results from our non-human primate safety study, and ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... ... CE Certificate of Conformity for the Smart System® 20/20. CE Certification builds upon ... industry standards and specifications such as ANSI, ISO and proven test methods used ...
(Date:3/27/2017)... ... March 27, 2017 , ... Osteitis pubis ... type of groin injury, it occurs when the muscles around the pelvis become ... and around the lower torso, as well as accompanying tenderness and weakness. Without ...
(Date:3/27/2017)... ... 2017 , ... EpiGentek , a Farmingdale, NY-based biotech ... methylation “gold rush” with their established portfolio of optimized assay kits that measure ... m6A , RNA methylation has received a new burst in interest as ...
(Date:3/27/2017)... ... , ... Janet Schloz is still in shock after receiving a $2,500 Academic Award from ... time,” she said. , She thinks the coming week is going to be a very ... have to help my students.” , The award will allow the 4th grade teacher at ...
(Date:3/27/2017)... ... March 27, 2017 , ... Sodium determination is consistently ... and require expert user knowledge. In a live webinar on April 11th and ... yet highly accurate, determination of sodium. , It has long been known that ...
Breaking Medicine News(10 mins):